Skip to main content
NewslettersWatchlist

Medicenna Therapeutics Corp(MDNA-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.41
Day High1.58
Open:1.53
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Reports Second Quarter Fiscal 2025 Financial Results and Corporate Update
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Upcoming Presentations at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO) and the 2024 San Antonio Breast Cancer Symposium (SABCS)
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDAยฎ (pembrolizumab) at the 39th Annual Meeting of SITC
Motley Fool
1 High-Yield Dividend ETF to Buy to Generate Passive Income
GlobeNewswire
Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
OTC Markets Group Welcomes Medicenna Therapeutics Corp. to OTCQX
GlobeNewswire
Medicenna to Present Clinical and Preclinical Data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
GlobeNewswire
Medicenna Announces Results of Annual Meeting of Shareholders
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
GlobeNewswire
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
Baystreet
Stocks in play: Medicenna Therapeutics Corp.
GlobeNewswire
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
GlobeNewswire
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)
GlobeNewswire
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
AI-generated - The Globe and Mail
Medicenna Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (MDNA)
GlobeNewswire
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
GlobeNewswire
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe

Profile

Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.